Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
53 hedge funds and large institutions have $299M invested in Aerie Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 9 closing their positions.
92% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 12
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
19% more capital invested
Capital invested by funds: $252M → $299M (+$46.7M)
8% more funds holding
Funds holding: 49 → 53 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$5.36M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.29M |
| 3 |
IHM
Iguana Healthcare Management
New York
|
+$1.97M |
| 4 |
MSA
Mason Street Advisors
Milwaukee,
Wisconsin
|
+$1.81M |
| 5 |
CNB
City National Bank
Beverly Hills,
Delaware
|
+$1.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$7.03M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.54M |
| 3 |
Millennium Management
New York
|
-$1.92M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.8M |
| 5 |
PA
Perceptive Advisors
New York
|
-$1.79M |
AERI Hedge Fund Activity: Q1 2014 in Review
53 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q1 2014, worth a combined $299M — up 19% from $252M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AERI positions and 9 closed out — a net gain of 4 holders — while 23 added to existing stakes and 12 trimmed.
The largest buyer was Deerfield Management, adding an estimated $5.36M. The largest seller was Broadfin Capital, exiting entirely with an estimated $7.03M sold.
- 53 institutional investors held Aerie Pharmaceuticals (AERI) as of Q1 2014, up from 49 in Q4 2013.
- Funds reported $299M of Aerie Pharmaceuticals stock for Q1 2014, up 19% quarter-over-quarter.
- 13 funds opened new Aerie Pharmaceuticals positions in Q1 2014 and 9 closed out, a net change of +4 holders.
- The largest Aerie Pharmaceuticals buyer in Q1 2014 was Deerfield Management, an estimated $5.36M added.
- The largest Aerie Pharmaceuticals seller in Q1 2014 was Broadfin Capital, an estimated $7.03M sold.
Based on aggregated 13F filings for Q1 2014.